| 000 | 01640 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517211001.0 | ||
| 264 | 0 | _c20190625 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1538-8514 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-17-0834 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTsai, Cheng-Yu | |
| 245 | 0 | 0 |
_aAPTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _c06 2018 |
||
| 300 |
_a1167-1176 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBRCA1 Protein _xdeficiency |
| 650 | 0 | 4 |
_aBRCA2 Protein _xdeficiency |
| 650 | 0 | 4 |
_aBreast Neoplasms _xgenetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aDNA Damage _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xpharmacology |
| 650 | 0 | 4 |
_aPhenanthrolines _xpharmacology |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aSun, Si | |
| 700 | 1 | _aZhang, Hongying | |
| 700 | 1 | _aLocal, Andrea | |
| 700 | 1 | _aSu, Yongxuan | |
| 700 | 1 | _aGross, Larry A | |
| 700 | 1 | _aRice, William G | |
| 700 | 1 | _aHowell, Stephen B | |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 17 _gno. 6 _gp. 1167-1176 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-17-0834 _zAvailable from publisher's website |
| 999 |
_c28258755 _d28258755 |
||